OTCQB:SCNX 4 November 2025

Scienture Holdings (SCNX) Surges on Coverage Breakthrough – Can This Pharma Underdog Deliver?

Scienture (SCNX) shares surged 40% to $0.99 pre-market Nov. 4 after its hypertension drug Arbli™ was added to major insurance formularies, expanding coverage to over 100 million people. The company reported just $0.13 million in revenue and a $20 million net loss over the past year. SCNX trades near $0.71, down from a 52-week high of $8.81. Analysts remain cautious, citing high cash burn and uncertain Arbli sales.

4 November 2025

OTCQB:SCNX·Stock Market

Nevada Temporarily Bans Prediction Market Firm Kalshi Over Gaming License Dispute
March 20, 2026, 2:30 PM EDT. Kalshi, a prediction markets platform offering event-based contracts on sports, elections, and entertainment, was temporarily banned in Nevada by a 14-day restraining order from the First Judicial District Court. The ruling prohibits Kalshi from operating its derivatives exchange without a gaming license, marking the first state-level forced cessation for the company. The ban follows earlier Nevada cease-and-desist actions and precedes a likely extension through the legal case, said gaming attorney Daniel Wallach. The dispute comes amid mounting regulatory scrutiny nationally, including criminal charges from Arizona and ongoing battles in multiple states. Kalshi contends its sports contracts are financial swaps, not gambling, a view supported by the federal Commodity Futures Trading Commission, which claims jurisdiction over these markets. This case highlights tensions between state gambling laws and federally regulated prediction markets.